These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22183247)

  • 1. Epidemiology of recurrent venous thrombosis.
    Ribeiro DD; Lijfering WM; Barreto SM; Rosendaal FR; Rezende SM
    Braz J Med Biol Res; 2012 Jan; 45(1):1-7. PubMed ID: 22183247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment for recurrent venous thrombosis.
    Kyrle PA; Rosendaal FR; Eichinger S
    Lancet; 2010 Dec; 376(9757):2032-9. PubMed ID: 21131039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of anticoagulation treatment in patients with venous thromboembolism.
    Kaatz S; Qureshi W; Fain C; Paje D
    J Am Osteopath Assoc; 2010 Nov; 110(11):638-44. PubMed ID: 21135195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment and novel therapeutic approaches: reducing the incidence and recurrence of deep vein thrombosis in the surgical patient. Conclusion.
    Laird L; Wille-Jørgensen P
    Orthopedics; 2000 Jun; 23(6 Suppl):s655-6. PubMed ID: 10875432
    [No Abstract]   [Full Text] [Related]  

  • 6. Deep vein thrombosis and pulmonary embolism.
    Di Nisio M; van Es N; Büller HR
    Lancet; 2016 Dec; 388(10063):3060-3073. PubMed ID: 27375038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment ultrasound-detected residual venous thrombosis: a risk factor for recurrent venous thromboembolism and mortality.
    Savory L; Harper P; Ockelford P
    Curr Opin Pulm Med; 2007 Sep; 13(5):403-8. PubMed ID: 17940485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recurrence risk in venous thromboembolic disease after anticoagulation discontinuation].
    Calvo Romero JM
    Med Clin (Barc); 2013 Apr; 140(7):310-3. PubMed ID: 22995846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study.
    Evans A; Davies M; Osborne V; Roy D; Shakir S
    BMJ Open; 2020 Nov; 10(11):e038102. PubMed ID: 33148732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-Based Therapies for Pharmacologic Prevention and Treatment of Acute Deep Vein Thrombosis and Pulmonary Embolism.
    Jacobs B; Henke PK
    Surg Clin North Am; 2018 Apr; 98(2):239-253. PubMed ID: 29502769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism: "... an ounce of prevention is worth a pound of cure".
    Goldhaber SZ; Ageno W
    Thromb Haemost; 2015 Jun; 113(6):1174-5. PubMed ID: 25947622
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
    Kearon C; Akl EA
    Blood; 2014 Mar; 123(12):1794-801. PubMed ID: 24497538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis.
    Malato A; Saccullo G; Iorio A; Ageno W; Siragusa S
    Curr Pharm Des; 2010; 16(31):3483-6. PubMed ID: 20858182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.
    Roderick P; Ferris G; Wilson K; Halls H; Jackson D; Collins R; Baigent C
    Health Technol Assess; 2005 Dec; 9(49):iii-iv, ix-x, 1-78. PubMed ID: 16336844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism.
    Kyrle PA; Eichinger S
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):471-4. PubMed ID: 13677265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.